xeroderma pigmentosum group F
disease diseaseOn this page
Also known as ERCC4 xeroderma pigmentosumxeroderma pigmentosum caused by mutation in ERCC4xeroderma pigmentosum group type Fxeroderma pigmentosum, complementation group Fxeroderma pigmentosum, complementation group type Fxeroderma pigmentosum, group Fxeroderma pigmentosum, type 6XP, group FXP-FXP6XPF
Summary
xeroderma pigmentosum group F (MONDO:0010215) is a disease caused by ERCC4 (GenCC Definitive), with 1 cohort gene.
At a glance
- Causal gene: ERCC4 (GenCC Definitive)
- Cohort genes: 1
- ClinVar variants: 850
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | xeroderma pigmentosum group F |
| Mondo ID | MONDO:0010215 |
| MeSH | C562592 |
| OMIM | 278760 |
| Orphanet | 276264 |
| DOID | DOID:0110848 |
| NCIT | C3968 |
| SNOMED CT | 42530008 |
| UMLS | C0268140 |
| MedGen | 120612 |
| GARD | 0005628 |
| Is cancer (heuristic) | no |
Also known as: ERCC4 xeroderma pigmentosum · xeroderma pigmentosum caused by mutation in ERCC4 · xeroderma pigmentosum group F · xeroderma pigmentosum group type F · xeroderma pigmentosum, complementation group F · xeroderma pigmentosum, complementation group type F · xeroderma pigmentosum, group F · xeroderma pigmentosum, type 6 · XP, group F · XP-F · XP6 · XPF
Data availability: 850 ClinVar variants · 4 GenCC gene-disease records · 29 cell lines.
Disease family
Classification path: disease › human disease › disease by body system or component › syndromic disease › xeroderma pigmentosum-Cockayne syndrome complex › xeroderma pigmentosum group F
Related subtypes (5): xeroderma pigmentosum group D, xeroderma pigmentosum group G, xeroderma pigmentosum group B, xeroderma pigmentosum, type F/Cockayne syndrome, xeroderma pigmentosum, type G/Cockayne syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
600 retrieved; paginated sample, class counts are floors:
315 uncertain significance, 183 likely benign, 28 conflicting classifications of pathogenicity, 28 benign, 19 pathogenic, 10 likely pathogenic, 9 benign/likely benign, 8 pathogenic/likely pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1075759 | NM_005236.3(ERCC4):c.22C>T (p.Arg8Ter) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 1324343 | NM_005236.3(ERCC4):c.1197_1198insCA (p.Ala400fs) | ERCC4 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1338473 | NM_005236.3(ERCC4):c.579G>A (p.Trp193Ter) | ERCC4 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1400031 | NM_005236.3(ERCC4):c.557_558del (p.Phe186fs) | ERCC4 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1422307 | NM_005236.3(ERCC4):c.1251T>A (p.Cys417Ter) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 1452810 | NM_005236.3(ERCC4):c.58C>T (p.Arg20Ter) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 16579 | NM_005236.3(ERCC4):c.2304_2307del (p.Thr770fs) | ERCC4 | Pathogenic | no assertion criteria provided |
| 1803967 | NM_005236.3(ERCC4):c.2026G>T (p.Glu676Ter) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 2048716 | NM_005236.3(ERCC4):c.1447_1450del (p.Arg483fs) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 2151562 | NM_005236.3(ERCC4):c.68del (p.Val23fs) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 2181510 | NM_005236.3(ERCC4):c.872T>A (p.Leu291Ter) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 2425327 | NC_000016.9:g.(?14038570)(14038702_?)del | ERCC4 | Pathogenic | criteria provided, single submitter |
| 2425329 | NC_000016.9:g.(?14020398)(14022112_?)del | ERCC4 | Pathogenic | criteria provided, single submitter |
| 288748 | NM_005236.3(ERCC4):c.915del (p.Asn308fs) | ERCC4 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2923026 | NM_005236.3(ERCC4):c.663dup (p.Met222fs) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 2927079 | NM_005236.3(ERCC4):c.856C>T (p.Gln286Ter) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 2928951 | NM_005236.3(ERCC4):c.1376C>A (p.Ser459Ter) | ERCC4 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2931256 | NM_005236.3(ERCC4):c.938dup (p.Arg314fs) | ERCC4 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2931654 | NM_005236.3(ERCC4):c.886C>T (p.Gln296Ter) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 2931871 | NM_005236.3(ERCC4):c.849_856del (p.Leu284fs) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 2932701 | NM_005236.3(ERCC4):c.148C>T (p.Gln50Ter) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 2952742 | NM_005236.3(ERCC4):c.1402del (p.Arg468fs) | ERCC4 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 3243523 | NC_000016.9:g.(?14028029)(14031735_?)del | ERCC4 | Pathogenic | criteria provided, single submitter |
| 3578438 | NM_005236.3(ERCC4):c.1349G>A (p.Trp450Ter) | ERCC4 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 3602651 | NM_005236.3(ERCC4):c.1417dup (p.Gln473fs) | ERCC4 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 3748773 | NM_005236.3(ERCC4):c.891T>G (p.Tyr297Ter) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 4072059 | NM_005236.3(ERCC4):c.202G>T (p.Glu68Ter) | ERCC4 | Pathogenic | criteria provided, single submitter |
| 1066740 | NM_005236.3(ERCC4):c.1102+1G>T | ERCC4 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 135534 | NM_005236.3(ERCC4):c.2017+1G>A | ERCC4 | Likely pathogenic | criteria provided, single submitter |
| 1709151 | NM_005236.3(ERCC4):c.581del (p.Pro194fs) | ERCC4 | Likely pathogenic | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 11 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| ERCC4 | Definitive | Autosomal recessive | xeroderma pigmentosum group F | 11 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| ERCC4 | Orphanet:220295 | Xeroderma pigmentosum-Cockayne syndrome complex |
| ERCC4 | Orphanet:84 | Fanconi anemia |
| ERCC4 | Orphanet:90321 | Cockayne syndrome type 1 |
| ERCC4 | Orphanet:910 | Xeroderma pigmentosum |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| ERCC4 | HGNC:3436 | ENSG00000175595 | Q92889 | DNA repair endonuclease XPF | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| ERCC4 | DNA repair endonuclease XPF | Catalytic component of a structure-specific DNA repair endonuclease responsible for the 5-prime incision during DNA repair, and which is essential for nucleotide excision repair (NER) and interstrand cross-link (ICL) repair. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| ERCC4 | Other/Unknown | no | ERCC4_domain, XPF, RuvA_2-like |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| adrenal tissue | 1 |
| male germ line stem cell (sensu Vertebrata) in testis | 1 |
| sperm | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| ERCC4 | 242 | ubiquitous | marker | male germ line stem cell (sensu Vertebrata) in testis, adrenal tissue, sperm |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| ERCC4 | 2,102 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| ERCC4 | Q92889 | 13 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 5. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| HDR through Single Strand Annealing (SSA) | 1 | 292.8× | 0.005 | ERCC4 |
| Fanconi Anemia Pathway | 1 | 278.5× | 0.005 | ERCC4 |
| Dual Incision in GG-NER | 1 | 259.6× | 0.005 | ERCC4 |
| Formation of Incision Complex in GG-NER | 1 | 253.8× | 0.005 | ERCC4 |
| Dual incision in TC-NER | 1 | 173.0× | 0.006 | ERCC4 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| nucleotide-excision repair involved in interstrand cross-link repair | 1 | 5617.3× | 0.001 | ERCC4 |
| telomeric DNA-containing double minutes formation | 1 | 4213.0× | 0.001 | ERCC4 |
| negative regulation of protection from non-homologous end joining at telomere | 1 | 4213.0× | 0.001 | ERCC4 |
| negative regulation of telomere maintenance | 1 | 2808.7× | 0.001 | ERCC4 |
| negative regulation of telomere maintenance via telomere lengthening | 1 | 1404.3× | 0.002 | ERCC4 |
| UV protection | 1 | 1203.7× | 0.002 | ERCC4 |
| resolution of meiotic recombination intermediates | 1 | 936.2× | 0.002 | ERCC4 |
| double-strand break repair via nonhomologous end joining | 1 | 421.3× | 0.004 | ERCC4 |
| nucleotide-excision repair | 1 | 383.0× | 0.004 | ERCC4 |
| response to UV | 1 | 366.4× | 0.004 | ERCC4 |
| cellular response to UV | 1 | 295.6× | 0.005 | ERCC4 |
| telomere maintenance | 1 | 267.5× | 0.005 | ERCC4 |
| regulation of autophagy | 1 | 240.7× | 0.005 | ERCC4 |
| double-strand break repair via homologous recombination | 1 | 156.0× | 0.007 | ERCC4 |
| DNA repair | 1 | 63.8× | 0.016 | ERCC4 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| ERCC4 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| ERCC4 | 28 | Binding:28 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | ERCC4 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| ERCC4 | 28 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: ERCC4